HC Wainwright Forecasts Journey Medical FY2025 Earnings

Journey Medical Corporation (NASDAQ:DERM) – Investment analysts at HC Wainwright lowered their FY2025 earnings per share estimates for shares of Journey Medical in a research report issued to clients and investors on Thursday, November 13th. HC Wainwright analyst B. Folkes now expects that the company will post earnings of ($0.53) per share for the year, down from their prior forecast of ($0.45). HC Wainwright currently has a “Buy” rating and a $13.00 price target on the stock. The consensus estimate for Journey Medical’s current full-year earnings is ($1.02) per share. HC Wainwright also issued estimates for Journey Medical’s Q4 2025 earnings at ($0.10) EPS.

Several other equities research analysts also recently commented on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Journey Medical in a research report on Wednesday, October 8th. Lake Street Capital lifted their target price on Journey Medical from $9.00 to $13.00 and gave the company a “buy” rating in a research note on Wednesday, August 13th. Finally, Zacks Research raised shares of Journey Medical from a “strong sell” rating to a “hold” rating in a research report on Monday, October 13th. Three research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has an average rating of “Hold” and an average target price of $12.17.

Journey Medical Price Performance

DERM stock opened at $7.69 on Monday. Journey Medical has a one year low of $3.54 and a one year high of $9.40. The firm has a 50-day moving average of $7.66 and a two-hundred day moving average of $7.32. The firm has a market capitalization of $202.32 million, a PE ratio of -21.97 and a beta of 0.80. The company has a current ratio of 1.42, a quick ratio of 1.12 and a debt-to-equity ratio of 0.75.

Journey Medical (NASDAQ:DERM) last released its quarterly earnings results on Wednesday, November 12th. The company reported ($0.09) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.08) by ($0.01). The company had revenue of $17.63 million during the quarter, compared to analyst estimates of $18.85 million. Journey Medical had a negative net margin of 14.58% and a negative return on equity of 39.94%.

Institutional Trading of Journey Medical

A number of institutional investors have recently added to or reduced their stakes in the business. Titleist Asset Management LLC lifted its position in shares of Journey Medical by 18.3% in the first quarter. Titleist Asset Management LLC now owns 12,900 shares of the company’s stock worth $76,000 after buying an additional 2,000 shares during the last quarter. Police & Firemen s Retirement System of New Jersey acquired a new stake in shares of Journey Medical in the second quarter worth $29,000. Bank of America Corp DE increased its position in Journey Medical by 4,707.0% during the second quarter. Bank of America Corp DE now owns 4,134 shares of the company’s stock worth $30,000 after acquiring an additional 4,048 shares during the period. Raymond James Financial Inc. acquired a new position in Journey Medical during the 2nd quarter valued at $36,000. Finally, Pale Fire Capital SE grew its position in Journey Medical by 19.0% in the 2nd quarter. Pale Fire Capital SE now owns 32,458 shares of the company’s stock worth $233,000 after purchasing an additional 5,184 shares during the last quarter. 7.25% of the stock is currently owned by institutional investors and hedge funds.

Journey Medical Company Profile

Journey Medical Corporation focuses on the development and commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's marketed products include Qbrexza, a medicated cloth towelette for the treatment of primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug to treat severe recalcitrant nodular acne; and Amzeeq, a topical formulation of minocycline for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris.